The New Hedge Fund That Surged 200 Percent in 2020

Suvretta Capital affiliate Averill posted eye-popping returns, while Suvretta posted very strong gains of its own.

Stephen Taub January 11, 2021

(Marc McAndrews/Bloomberg)

Averill, the new biopharmaceutical fund managed by a team under the Suvretta Capital umbrella, posted blowout returns for its first partial year of trading, according to a communication sent to clients and seen by Institutional Investor.Averill, which manages about $350 million and began

To continue reading, subscribe now to Premium Journalism. Already a subscriber? login.

Contact Info

New York
1270 Avenue of the Americas, Suite 1100
New York, NY 10020
P: +1 212 224 3300

London
4 Bouverie Street
London EC4Y 8AX
P: +44 207 779 8888

Hong Kong
Unit 2488, 24/F
Lee Garden One,
33 Hysan Avenue
Causeway Bay, Hong Kong
P: +852 2912 8001

Corporate

About Us

Leadership Team

Careers

II Press Room

Digital

Masthead

Thought Leadership

Display Advertising

Reprints

FAQs

Events

Events Calendar

Memberships

Subscription

Subscribe to Premium

Register

Register for Free Account

Newsletters

Sign up for II newsletters

© 2025 Institutional Investor LLC. All material subject to strictly enforced copyright laws. Please read our Terms & Conditions, Modern Slavery Act Transparency Statement, Accessibility Statement and Privacy Policy before using the site.

4.12.03 build:2025-12-12 Login